Business Context and Reporting Period
This Form 8-K Current Report is filed by 60 Degrees Pharmaceuticals, Inc. on August 12, 2024. The report details the effective implementation of a reverse stock split for the Company's common stock, which became effective at 12:01 a.m. on the filing date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure changes rather than financial performance results.
Material Changes
- Reverse Stock Split Execution: The Company executed a 1-for-12 reverse stock split of its outstanding common stock.
- Shareholder Approval: Stockholders approved the amendment on July 16, 2024, authorizing a split ratio between 1-for-5 and 1-for-12. The Board finalized the ratio at 1-for-12 on July 19, 2024.
- Fractional Shares: No fractional shares were issued; fractional amounts were rounded up to one whole share.
- Security Identification: The Common Stock was assigned a new CUSIP number: 83006G203.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard legal disclaimers regarding the press release attached as Exhibit 99.1. The primary event reported is the structural change to the Company's equity.
Investor Verification Checklist
- Verify the new CUSIP number (83006G203) for trading purposes.
- Confirm the 1-for-12 split ratio applied to existing holdings.
- Review the treatment of fractional shares (rounded up to one whole share).
- Check the effective date of the split (August 12, 2024, at 12:01 a.m.).